Hanamura, Toru
Kitano, Shigehisa
Kagamu, Hiroshi
Yamashita, Makiko
Terao, Mayako
Tsuda, Banri
Okamura, Takuho
Kumaki, Nobue
Hozumi, Katsuto
Harada, Naoki
Iwamoto, Takayuki
Honda, Chikako
Kurozumi, Sasagu
Niikura, Naoki
Funding for this research was provided by:
Tokai University
Japan Society for the Promotion of Science (18K16266)
Article History
Received: 24 November 2021
Accepted: 28 February 2022
First Online: 16 May 2022
Competing interests
: Hiroshi Kagamu has an advisory role in ImmuniT Research Inc. Naoki Harada received a salary from Chugai Pharmaceutical. Shigehisa Kitano received honoraria from Ono Pharmaceutical Co., Bristol-Myers Squibb Co., Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., and MSD Co., Ltd. Hiroshi Kagamu received honoraria from AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb Co., Ltd. Naoki Niikura received honoraria from AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Eisai Co., Ltd., and Nippon Kayaku Co., Ltd. Shigehisa Kitano received research funding from Astellas Pharma Inc., Gilead Sciences Inc., Eisai Co., Ltd., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmgH, Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Takara Bio Inc., PACT Pharma, Inc., Chugai Pharmaceutical Co., Ltd., and MSD Co., Ltd. Naoki Niikura received research funding from Chugai Pharmaceutical Co., Ltd. The remaining authors declare no competing interests.